3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
4
Breast Neoplasms
4
Sarcoma
3
Ovarian Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Seminoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain
1
Osteosarcoma
1
Neoplasm Metastasis
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
pegfilgrastim
×
Clear all
NCT01879085
2022-09-21
GemTax
University of Pittsburgh
Phase 1/2
Completed
37 enrolled
17 charts